4 recruiting, 4 terminated, 2 active not recruiting, 2 withdrawn. 9 Phase 2, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 3, Active not recruiting 2, Terminated 2, Completed 1, Withdrawn 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Not applicable | 1 | Terminated 1 |
Follow 16-fluoroestradiol: new trials by email Literature Review of 16-fluoroestradiol trials Research Report on 16-fluoroestradiol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Capecitabine, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma | Phase 2 | Recruiting | University of Washington | 40 | 2025-11-17 | 2026-04-06 |
| Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 18 | 2024-07-23 | 2026-10-07 |
| [18F]FES PET/.CT in Uterine Cancer 18F-Fluoroestradiol - Uterine Cancer | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 30 | 2024-04-05 | 2026-06-05 |
| FES BPET-DBT in Newly Diagnosed Breast Cancer BPET/DBT imaging, 18F-FES - Breast Cancer | Early Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 20 | 2023-10-02 | 2026-02-27 |
| Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography - Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma | Phase 2 | Active not recruiting | University of Washington | 2 | 2021-07-10 | 2026-07-01 |
| TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH ESR-specific PET scan - Pulmonary Arterial Hypertension | Withdrawn | Vanderbilt University Medical Center | 2021-01-05 | 2025-01-03 | ||
| Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer biopsy or surgical pathology in metastases, 68Ga-HER2 affibody,18F-FDG, 18F-FES - Breast Cancer | Unknown | Fudan University | 50 | 2020-12-31 | 2022-04-20 | |
| Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS (18F)FES, Gadobenate dimeglumine - Breast Cancer, Ductal Carcinoma in Situ - Category | Phase 2 | Completed | University of Wisconsin, Madison | 12 | 2019-01-03 | 2025-02-12 |
| Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET F-18 Fluoroestradiol, Computed Tomography, Positron Emission Tomography - Breast Cancer | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2017-02-22 | 2020-05-12 | |
| [18F]FES PET/CT in PAH [18F] FES - Pulmonary Arterial Hypertension | Terminated | University of Pennsylvania | 5 | 2016-07-01 | 2021-05-18 | |
| FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory Biomarker Analysis - HER2/Neu Negative, Progesterone Receptor Negative | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 99 | 2016-05-04 | 2026-06-29 |
| [18F]FES PET/CT in Endocrine Refractory Breast Cancer [18F]FES - Estrogen Receptor Positive Breast Cancer, Breast Neoplasm | Phase 2 | Terminated | University of Pennsylvania | 6 | 2015-10-15 | 2026-06-11 |
| Assessment of Performance of [18F]-FES for Endometriosis Diagnosis [18F]FES (16α-[18F]Fluoro-17β-estradiol) - Endometriosis | Phase 2 | Terminated | University Hospital, Angers | 31 | 2012-06-01 | 2018-09-17 |
| F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Fludeoxyglucose F-18 - Estrogen Receptor Positive, Recurrent Breast Carcinoma | Not applicable | Terminated | University of Washington | 29 | 2010-09-15 | 2021-06-30 |
Breast Neoplasms (8) · Pulmonary Arterial Hypertension (2) · Endometriosis (1) · Hypertension, Pulmonary (1) · Uterine Neoplasms (1)
University of Washington (3) · Abramson Cancer Center at Penn Medicine (2) · University of Pennsylvania (2) · City of Hope Medical Center (1) · Fudan University (1) · National Cancer Institute (NCI) (1) · University Hospital, Angers (1) · University of Texas Southwestern Medical Center (1) · University of Wisconsin, Madison (1) · Vanderbilt University Medical Center (1)
United States (12) · China (1) · France (1)
Hannah Linden (2) · Amy Fowler (1) · Christine Edmonds, MD (1) · David Mankoff, MD, PhD (1) · David Mankoff, MD. PhD (1) · Eric D Austin, MD, MSCI (1) · Farrokh Dehdashti (1) · Jose G Bazan (1) · Natasha Hunter, MD (1) · Neil Taunk, MD (1) · Olivier Couturier, PU-PH (1) · Philippe Descamps, PU-PH (1) · Rathan Subramaniam, MD (1) · Xichun Hu, MD, PhD (1)
KL2TR000428 (1), P01CA042045 (1), P30CA014520 (1), P30CA033572 (1), U01CA148131 (1), U10CA180820 (1)